3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Fluorouracil
131
Leucovorin
127
Oxaliplatin
93
Bevacizumab
86
Irinotecan
74
Capecitabine
63
Cetuximab
47
Folfox protocol
32
Panitumumab
18
regorafenib
16
trifluridine tipiracil drug combination
15
Drug Therapy
14
Chemotherapy, Adjuvant
13
IFL protocol
10
Floxuridine
10
Radiotherapy
9
Tegafur
7
Neoadjuvant Therapy
7
Levoleucovorin
7
Laparoscopy
7
Aspirin
7
pembrolizumab
6
Trifluridine
6
Celecoxib
6
atezolizumab
5
XELOX
5
Mitomycin
5
Colonoscopy
5
tipiracil
4
sintilimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colorectal Neoplasms
×
lenvatinib
×
Clear all
NCT04776148
2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3
Completed
563 enrolled
32 charts